和美药业-B(00054)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

00054 和美药业-B

待上市 11-03 16:00:00

0.000

-38.600

-100.00%

最高0.000	最低0.000	成交量0.00
今开0.000	昨收38.600	日振幅0.00%
总市值0.00	流通市值0.00	总股本4.52亿
成交额0.00	换手率0.00%	流通股本4.52亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"00054","market":"HK","secType":"STK","nameCN":"和美药业-B","latestPrice":0,"timestamp":1793692800000,"preClose":38.6,"halted":7,"volume":0,"delay":0,"changeRate":-1,"floatShares":452056576,"shares":452056576,"eps":0,"marketStatus":"待上市","change":-38.6,"latestTime":"11-03 16:00:00","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794187800000},"marketStatusCode":8,"adr":0,"listingDate":1794153600000,"exchange":"SEHK","adjPreClose":38.6,"openAndCloseTimeList":[[1793669400000,1793678400000],[1793682000000,1793692800000]],"volumeRatio":0,"ipoDetail":{"name":"和美药业－Ｂ","exchange":"SEHK","listingDate":"2026-11-09","sharesOutstanding":452056576,"sharesFloat":309179480,"offerAmount":55210000,"priceRange":"15.50  -  18.90","market":"HK","openProspectusDate":"2026-10-30","openProspectusUrl":"https://ossnoticepdf.iqdii.com/stockdata/notice/00054/2026/2026103000030_c.pdf","purchaseBeginDate":"2026-10-30","purchaseEndDate":"2026-11-04","winningDate":"2026-11-05","currency":"HKD","minPurchaseQuantity":100,"peRate":-54.21,"use":"1、约55.5%或488.0百万港元将用于Mufemilast（核心产品）－研发及商业化；\n2、约4.5%或39.6百万港元将用于Hemay022（关键产品）－研发；\n3、约20.0%或175.9百万港元将用于Hemay181（关键产品）－研发；\n4、约10.0%或87.9百万港元将用于其他管线产品－研发；\n5、约10.0%或87.9百万港元一般公司及营运资金。","industryId":"204005","industryName":"医疗保健","business":"公司是一家创新驱动的生物制药公司，致力于发现和开发针对自身免疫性疾病和肿瘤的小分子药物，并在Ps、BD和IBD和创新化学疗法开发中处于行业前沿地位。","subscribed":1.47,"marketCap":7006999999.999999,"minimumCapital":1909.06,"overAllotment":true,"lotSize":100,"issueOpenRate":0.1,"subscribeGear":"100,200,300,400,500,600,700,800,900,1000,1500,2000,2500,3000,3500,4000,4500,5000,6000,7000,8000,9000,10000,20000,30000,40000,50000,60000,70000,80000,90000,100000,200000,300000,400000,500000,600000,700000,800000,900000,1000000,2000000,2760500","issueRatio":0.1,"offeringMechanism":"B"},"greyMarketDetail":{"greyDate":"2026-11-06","greyDateTimestamp":1793894400000,"greyOpeningTime":1793952900000,"greyClosingTime":1793961000000,"showGreyQuote":false,"openProspectusDate":"2026-10-30","listingDate":"2026-11-09"},"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/00054","defaultTab":"news","newsList":[{"id":"2680232217","title":"和美药业开启招股：拟募资8.6亿 11月9日上市 4个月亏3125万","url":"https://stock-news.laohu8.com/highlight/detail?id=2680232217","media":"雷递网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680232217?lang=zh_cn&edition=full","pubTime":"2026-11-03 19:46","pubTimestamp":1793706410,"startTime":"0","endTime":"0","summary":"赣州和美药业股份有限公司（简称：“和美药业”，股票代码：“00054”）日前开启招股，准备2026年11月9日在港交所上市。","market":"sh","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20261103/6392933198464049915652582.jpeg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20261103/6392933198464049915652582.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n35616/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["IPOS","00054"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161053870","title":"新股招股 | 和美药业-B今起招股，一手入场费1909.06港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1161053870","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1161053870?lang=zh_cn&edition=full","pubTime":"2026-10-30 09:33","pubTimestamp":1793323990,"startTime":"0","endTime":"0","summary":"截至最后实际可行日期，公司有一种核心产品Mufemilast和五种小分子候选药物。于2025年9月，Mufemilast已于中国获得NDA批准以用于治疗中重度斑块状银屑病。该产品已就BD获FDA授出孤儿药资格认定。公司已订立基石投资协议，据此，基石投资者已同意在遵守若干条件的情况下，按发售价认购或促使其指定实体认购可购入的发售股份有关数目，总金额为2900万美元。公司估计本次发售的所得款项净额将约为8.793亿港元。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"3430ee0e05254278b5a3da84a7b77b4c","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"新股招股 | 和美药业-B今起招股，一手入场费1909.06港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00054"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679567532","title":"和美药业今起招股，获广发基金、汇添富等基石认购超2.2亿港元，预计11月9日挂牌上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2679567532","media":"独角兽早知道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679567532?lang=zh_cn&edition=full","pubTime":"2026-10-30 08:33","pubTimestamp":1793320380,"startTime":"0","endTime":"0","summary":"截至2026年，国内已有18种获批治疗银屑病的靶向药物，包括5种小分子药物和13种生物制剂。Mufemilast目前的年治疗费用约8.69万元，尚未进入国家医保目录。截至2026年4月30日，公司持有的现金及现金等价物为4508万元。和美药业的收入结构在2027年之前，将高度依赖Mufemilast一款产品的商业化表现。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzU3MTY1MzExOQ==&mid=2247615184&idx=5&sn=48ff00283db606d8eb73d34d91d500fb&chksm=fd1960b811bc531f88f0598cb394ac6f2ee3b8f7680c6358db2e3e33921da269f4637ce44128&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IPOS","00054"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679258221","title":"和美药业-B(00054)10月30日-11月4日招股 拟全球发售5521万股H股 引入广发基金管理、汇添富基金等基石投资者","url":"https://stock-news.laohu8.com/highlight/detail?id=2679258221","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679258221?lang=zh_cn&edition=full","pubTime":"2026-10-30 07:22","pubTimestamp":1793316137,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和美药业-B 于2026年10月30日-2026年11月4日招股，拟全球发售5521万股H股，其中，香港公开发售占约10%，国际发售占约90%。其中包括已获国家药监局批准的自身免疫药物Mufemilast、两款候选药物和三款肿瘤候选药物。集团于2024年及2025 年以及截至2025年及2026年4月30日止四个月的除税前亏损分别为人民币1.23亿元、人民币1.3亿元、人民币5180万元及人民币3240万元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1515762.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00054","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164784326","title":"赫美医药（00054）全球发售要点","url":"https://stock-news.laohu8.com/highlight/detail?id=1164784326","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164784326?lang=zh_cn&edition=full","pubTime":"2026-10-30 07:11","pubTimestamp":1793315477,"startTime":"0","endTime":"0","summary":"赫美医药是一家成立于2002年的生物制药企业，专注于自主研发小分子药物，主要针对自身免疫及肿瘤领域。公司核心产品为Mufemilast，一种PDE4/PDE4B抑制剂，用于中重度斑块型银屑病，已于2025年9月获得中国NDA批准，并于2026年7月开始在国内商业化上市销售。公司尚未在往绩记录期内产生产品销售收入，但在研发方面投入较大，目前在多种自身免疫及肿瘤适应症中持续开展临床试验并推进产业化。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"赫美医药（00054）全球发售要点","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00054"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115747310","title":"新股速递：赣州和美药业(00054)启动全球发售，最高发售价每股18.90港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1115747310","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1115747310?lang=zh_cn&edition=full","pubTime":"2026-10-30 06:35","pubTimestamp":1793313306,"startTime":"0","endTime":"0","summary":"赣州和美药业股份有限公司宣布，于2026年10月30日至11月4日招股，拟采用香港公开发售与国际配售并行的方式在全球发售合共55,210,000股H股，其中香港公开发售5,521,000股，国际配售49,689,000股。本次发售的最高发售价为每股H股18.90港元，预计于发售价厘定后视市况及认购情况在香港公开发售与国际配售之间进行重新分配，并可能行使最高不超过初步发行规模15%的超额配股权。假设发售价每股17.30港元且超额配股权未行使，预期募资净额约8.79亿港元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"新股速递：赣州和美药业(00054)启动全球发售，最高发售价每股18.90港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00054"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124547746","title":"赣州和美药业（0054）启动全球发售 最高定价18.90港元每股","url":"https://stock-news.laohu8.com/highlight/detail?id=1124547746","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124547746?lang=zh_cn&edition=full","pubTime":"2026-10-30 06:11","pubTimestamp":1793311872,"startTime":"0","endTime":"0","summary":"2026年10月30日，赣州和美药业股份有限公司正式公布全球发售计划。本次全球发售总规模为55,210,000股H股，设有超额配股权；其中，香港公开发售初步提呈5,521,000股H股，占全球发售初步可供认购股份总数约10%；国际发售初步提呈49,689,000股H股，占比约90%，并同样可予调整及视乎超额配股权行使情况而定。投资者认购香港发售股份时，需按最高发售价18.90港元及相关费用预缴款项，每手100股最高申购金额为1,909.06港元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00054"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679401458","title":"和美药业通过港交所聆讯，小分子创新药企的突围路径","url":"https://stock-news.laohu8.com/highlight/detail?id=2679401458","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679401458?lang=zh_cn&edition=full","pubTime":"2026-10-29 19:59","pubTimestamp":1793275183,"startTime":"0","endTime":"0","summary":"和美药业正式通过港交所聆讯。","market":"sg","thumbnail":"https://img7.gelonghui.com/column/2.png?guru_height=540&guru_width=375","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2.png?guru_height=540&guru_width=375"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/7211630","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["00054"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677963871","title":"新股解读｜Mufemilast商业化启幕，和美药业18A上市进入倒计时","url":"https://stock-news.laohu8.com/highlight/detail?id=2677963871","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677963871?lang=zh_cn&edition=full","pubTime":"2026-10-22 20:24","pubTimestamp":1792671864,"startTime":"0","endTime":"0","summary":"2025年9月，Mufemilast已获得国家药监局NDA批准，用于治疗中重度斑块状银屑病，成为公司首款实现商业化的产品。Mufemilast的临床数据展现出显著的差异化优势。除银屑病外，Mufemilast的多适应症拓展正在稳步推进。公司已就Mufemilast治疗白塞病获得FDA授予的孤儿药资格认定，并计划于2026年12月底前与FDA展开正式沟通，探讨直接在美国开展III期临床试验的可行性。截至目前，公司已向九家经销商供应共2000盒Mufemilast，分销范围覆盖陕西、江西、北京、山东、四川、河南、宁夏及广东。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1511075.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00054","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677646009","title":"和美药业通过上市聆讯：4个月亏3125万 张和胜夫妇控制47%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2677646009","media":"雷递网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677646009?lang=zh_cn&edition=full","pubTime":"2026-10-21 10:53","pubTimestamp":1792551204,"startTime":"0","endTime":"0","summary":"赣州和美药业股份有限公司（简称：“和美药业”）日前通过上市聆讯，准备在港交所上市。","market":"us","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20261021/6392817678693199411283196.jpeg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20261021/6392817678693199411283196.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n35445/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["IPOS","00054"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677034612","title":"新股消息 | 和美药业通过港交所聆讯 两年累亏2.53亿 核心产品刚起步商业化","url":"https://stock-news.laohu8.com/highlight/detail?id=2677034612","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677034612?lang=zh_cn&edition=full","pubTime":"2026-10-21 06:57","pubTimestamp":1792537038,"startTime":"0","endTime":"0","summary":"目前，公司拥有核心产品Mufemilast和五种小分子候选药物。于2025年9月，Mufemilast已于中国获得NDA批准以用于治疗中重度斑块状银屑病。根据市场资料，中国HER2阳性乳腺癌药物市场规模估计将从2021年的人民币114亿元增长至2025年的人民币165亿元，复合年增长率为9.7%。未来，中国HER2阳性乳腺癌药物市场规模将进一步增长至2028年的人民币233亿元及2032年的人民币377亿元，自2025年至2028年的复合年增长率为12.2%及自2028年至2032年则为12.8%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1509825.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00054"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655366552","title":"和美药业获IPO备案：亏损1.3亿 张和胜夫妇控制47%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2655366552","media":"雷递网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655366552?lang=zh_cn&edition=full","pubTime":"2026-07-31 20:06","pubTimestamp":1785499564,"startTime":"0","endTime":"0","summary":"赣州和美药业股份有限公司（简称：“和美药业”）今日获IPO备案，拿到了上市的钥匙。","market":"sh","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260731/6392112514584422993430536.jpeg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260731/6392112514584422993430536.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n34534/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["BK4127","00054","KCE","REDS","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655507733","title":"新股消息 | 和美药业港股IPO及境内未上市股份“全流通”获中国证监会备案","url":"https://stock-news.laohu8.com/highlight/detail?id=2655507733","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655507733?lang=zh_cn&edition=full","pubTime":"2026-07-31 18:51","pubTimestamp":1785495097,"startTime":"0","endTime":"0","summary":"","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1474751.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4127","KCAI","REDS","KCE","00054","VXUS","BK4588","BK4585","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646399796","title":"和美药业-B，递交招股书，拟赴香港上市 | 医疗健康企业.IPO上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2646399796","media":"港澳IPO上市","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2646399796?lang=zh_cn&edition=full","pubTime":"2026-06-27 09:14","pubTimestamp":1782522840,"startTime":"0","endTime":"0","summary":"","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzI1NTA3NDA2MA==&mid=2247505559&idx=8&sn=258990ba5f21ad99b42f6658a3452bd7&chksm=eb5fbe2e4e9c45b1bd61a00a4bb8515313dfa2a4ce911978e234029597fc84692dd90655bc0c&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00054"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hemay.com.cn/","compareEarnings":[{"period":"1week","weight":0.021},{"period":"1month","weight":-0.0186},{"period":"3month","weight":-0.0922},{"period":"6month","weight":-0.1164},{"period":"1year","weight":-0.1006},{"period":"ytd","weight":-0.0821}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"赣州和美药业股份有限公司是一家创新药企业，主要从事药物自主研发与产业化，研发管线覆盖自身免疫疾病和肿瘤等领域。","exchange":"SEHK","name":"和美药业-B","nameEN":"Ganzhou Hemay Pharmaceutical"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"和美药业-B(00054)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供和美药业-B(00054)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"和美药业-B,00054,和美药业-B股票,和美药业-B股票老虎,和美药业-B股票老虎国际,和美药业-B行情,和美药业-B股票行情,和美药业-B股价,和美药业-B股市,和美药业-B股票价格,和美药业-B股票交易,和美药业-B股票购买,和美药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"和美药业-B(00054)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供和美药业-B(00054)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}